DEMETEAR_en

13 Dec 2021 | Unclassified

DEMETEAR With an occurrence of approximately 2500 new cases per year in France, B-cell chronic lymphocytic leukaemia (CLL) is a major public health issue. The clinical management of patients, both in the first line and in relapse, has been revolutionised by the...

IMMUSPHINX_en

13 Dec 2021 | Unclassified

IMMUSPHINX: Targeting sphingolipid metabolism to improve the efficacy of immunotherapies in melanoma. Immune checkpoint inhibitors (ICIs) have shown an unprecedented and long-lasting anti-tumour response in patients with metastatic melanoma. To increase the proportion...

PIPgene_en

13 Dec 2021 | Unclassified

PIPgen: a new Innovative Training Network to put PI3K/PTEN related diseases under the spotlight PIPgen brings together 9 leading European basic and clinical institutions and 3 private companies experts in the PI3K/PTEN field, to train 15 researchers at the Phd level...

ONCOPOLE_en

13 Dec 2021 | Unclassified

ONCOPOLE – Functional analysis of the inherited N363K POLE mutation in highly aggressive colon cancers and glioblastomas In rare cases, the occurrence of cancer is linked to an inherited genetic mutation, in which case there is a familial predisposition. Several...

MITHAML_en

13 Dec 2021 | Unclassified

MITHAML – Metabolic heterogeneity in acute myeloid leukaemia Accumulating evidence indicates that metabolism is involved in the drug resistance that develops in acute myeloid leukaemia (AML). However, approaches have so far assessed metabolism as a whole,...

PROTEOblood_en

10 Dec 2021 | Unclassified

PROTEOblood : Development of new therapies against two subtypes of lymphoma and leukaemia. Significant progress has recently been made in the diagnosis and selective treatment of certain blood cancers. However, most of these malignancies remain incurable. There is...